Mammoth Biosciences, Inc., a biotechnology company, develops clustered regularly interspaced short palindromic repeats (CRISPR0 solutions. It offers DETECTRTM that searches for the presence of specific nucleic acids in a sample that are indicative of disease, providing actionable clinical information for various diagnostic applications, such as single nucleotide polymorphisms (SNP), bacterial infections, cancer screening and profiling, antimicrobial resistance, and viral infections. The company also provides CRISPR-Cas systems to edit the genome for therapeutic applications, including immuno-oncology, autoimmune diseases, and liver diseases. Its solutions are used in healthcare, agriculture, environmental monitoring, biodefense, and other applications. Mammoth Biosciences, Inc. was formerly known as Apheleia Diagnostics, Inc. The company was founded in 2017 and is based in South San Francisco, California.